Revelation Biosciences, Inc.
REVB
$3.08
$0.082.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.43M | 4.54M | 4.70M | 4.60M | 4.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.98M | 8.55M | 9.53M | 8.94M | 8.66M |
| Operating Income | -7.98M | -8.55M | -9.53M | -8.94M | -8.66M |
| Income Before Tax | -15.04M | -15.52M | -15.90M | -8.96M | -120.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.04 | -15.52 | -15.90 | -8.96 | -0.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.04M | -15.52M | -15.90M | -8.96M | -120.30K |
| EBIT | -7.98M | -8.55M | -9.53M | -8.94M | -8.66M |
| EBITDA | -7.95M | -8.52M | -9.50M | -8.91M | -8.63M |
| EPS Basic | -139.82 | -268.07 | -413.66 | -424.86 | -465.56 |
| Normalized Basic EPS | -87.39 | -167.55 | -258.54 | -265.54 | -240.93 |
| EPS Diluted | -139.88 | -268.18 | -413.78 | -424.98 | -465.82 |
| Normalized Diluted EPS | -87.39 | -167.55 | -258.54 | -265.54 | -240.93 |
| Average Basic Shares Outstanding | 684.30K | 354.30K | 203.30K | 116.60K | 48.50K |
| Average Diluted Shares Outstanding | 684.30K | 354.30K | 203.30K | 116.60K | 63.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |